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Dirt is a microbiological metropolis, 
with thousands of bacterial species 
competing with each other for 
nutrients and space. The fruits of 
this competition, such as the 
antibiotics, have been some of the 
most important drugs ever 
discovered. TerraGen Diversity 
Inc. (Vancouver, Canada) and 
ChromaXome Corp. (La Jolla, 
California) think that the search for 
such drugs has just begun. They are 
scrutinizing the vast number of soil 
bacteria that have thus far been both 
unculturable and unexamined. 
Mike Gilman, who is involved 
with a similar but “embryonic” 
project at Ariad Pharmaceuticals, 
Inc. (Cambridge, Massachusetts), 
says there is no shortage of 
potentially interesting compounds. 
“I feel like the whole world is our 
playground now,” he says. “With 
this rich bounty of natural products, 
there are about a zillion things you 
would want to try them on.” 
Bigger is better 
Natural product isolation has 
traditionally involved the testing of 
crude environmental samples, 
followed by painstaking and 
laborious purification procedures 
using large amounts of natural 
material. The idea that has all these 
companies excited is one aspect of 
the new field of combinatorial 
biology. It involves the isolation of 
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large fragments of genomic DNA, 
fragments that can then direct the 
synthesis of novel natural products. 
“Antibiotics require a lot of 
enzymes for their synthesis, but the 
genes are contiguous,” explains Jo 
Handelsman, who works at the 
University of Wisconsin and 
collaborates with Gilman. An entire 
synthetic pathway can therefore be 
captured on a single bacterial 
artificial chromosome (BAC), and the 
researcher can directly test for the 
end product. 
There are complications, 
however. The multiple genes on the 
clones retain the transcriptional 
signals from their diverse microbial 
owners, and no single host cell can 
guarantee the expression of all the 
clones. The best candidate host is 
one of the various species of 
Streptomyces, themselves a subset of 
the Actinomycetes. “The lion’s 
share of commercially successful 
pharmaceuticals has come from 
Actinomycetes, and many of [those 
drugs] have come from 
Streptomyces,” says David Sherman, 
Senior Director at ChromaXome. 
Streptomyces can express genes from 
most Actinomycetes, a class of 
bacteria that has yielded the 
antibiotics erythromycin and 
tetracycline, and the 
immunosuppressant FK506. 
The other major problem is 
retrieving the DNA intact. “Your 
sample starts out looking like mud,” 
says Handelsman, “and cloning 
from that is a challenge.” 
Decomposing organic matter yields 
a complex mix of organic acids 
termed humic acid, and many of 
these compounds both degrade and 
copurify with DNA. “It’s a major 
barrier to routinely generating 
libraries of a significant size,” says 
Joe McDermott, research director at 
TerraGen. “With standard 
techniques you will end up with 
shredded DNA.” 
The companies have, however, 
isolated DNA, with insert sizes 
ranging from “up to 80 kb” (Ariad) 
to 40-100 kb (TerraGen and 
ChromaXome). It is difficult to 
determine which sizes are obtained 
routinely, and which only 
occasionally, but ChromaXome 
claims that the high end of their 
range is the “typical” size, whereas 
TerraGen says that inserts of around 
40 kb are used in current operations. 
From fish pigments to drugs 
ChromaXome is a confident 
company for one so young. It was 
started just three years ago, initially 
to make colorful transgenic fish by 
manipulating pigment biosynthetic 
pathways. The natural product hunt 
began with marine bacteria, but dirt 
searching began in earnest when the 
company started a collaboration witk 
Bristol-Myers Squibb. 
“We’re not just going into any old 
backyard and digging in the dirt,” 
says Sherman. “We search for soil 
rich in Actinomycete DNA.” The 
researchers then select for DNA 
fragments with homology to known 
drug-synthesizing genes, before 
expressing the DNA in Streptomyces. 
With any luck, the selected 
fragments will contain the genes for a 
whole synthesis pathway. 
The next problem is one of 
numbers. “If you can make so many 
recombinants so easily,” asks 
Sherman, “how do you screen them?” 
ChromaXome’s solution is a 
technique called macrodroplets. 
These gel-like particles are formed 
when calcium ions are added to a 
solution of sodium alginate containing 
free-floating recombinant cells. On 
average one cell is trapped per 
macrodroplet. Once the cells have 
grown up and expressed their unique 
products, a reporter (such as drug- 
resistant bacteria) is layered on top. 
According to Sherman, the 
partnership with Bristol-Myers 
Squibb has already yielded “two new 
natural product entities, one of them 
a promising anti-infective useful 
against many drug-resistant 
organisms.” Other collaborations will 
come from ChromaXome’s 
acquisition by Trega Biosciences Inc. 
Under the name Houghten 
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Pharmaceuticals, Trega was an early 
player in the field of combinatorial 
chemistry, and Sherman believes the 
two companies are a good match. 
“We are taking advantage,” he says, 
“of combinatorial biology’s ability to 
provide novel templates for 
combinatorial chemistry libraries.” 
Shuffling and modifying 
Template modification is also on 
TerraGen’s agenda, but they are 
doing it in viva. “If you take a host 
with pathways that are functioning 
already,” says McDermott, “the 
libraries don’t have to produce the 
whole pathway, they just need to 
modify it to produce a novel product. 
Most of the specificity [in drug 
action] is determined by the 
modifications, so you are really 
dealing with the active part of the 
molecule. The opportunity for 
picking up novel active structures is 
fairly high.” 
The modifications can be 
detected by screening for activity 
against bacteria resistant to the 
original drug, or by detecting the 
new molecule by high performance 
liquid chromatography and mass 
spectroscopy. The latter task would 
be nearly impossible if the bacteria 
to be analyzed came directly from 
the soil but, says McDermott, “since 
we are dealing with clones in the 
same background, if you subtract a 
control background you will be 
looking at very few differences.” 
Modifying existing natural 
products is a good idea while the 
size of inserts hovers around 40 kb. 
“With that size you can get some 
small pathways,” says McDermott, 
“but others are larger than that so 
you’re not going to get a whole 
pathway.” Eventually, however, 
inserts will get bigger, and the 
modification program may give way 
to isolating entirely new pathways. 
“Pharmaceutical companies are 
really interested in truly new 
chemical entities,” says McDermott, 
“because then you have the 
potential to modify that entity 
biologically or chemically, and that 
increases the likelihood of ending 
up with a real product.” 
Looking for lichen 
For their soil samples, TerraGen has 
found the surrounding area of British 
Columbia to be sufficiently diverse. 
“British Columbia has quite a range 
of environments, from near Arctic to 
near desert, plus deep sea vents off 
Vancouver island,” says McDermott. 
Further DNA diversity comes from 
the collections of lichens. Lichens are 
an intricate combination of a fungus 
and either an algal or cyanobacterial 
species. The fungal host provides a 
suitable growth environment, and the 
algal or cyanobacterial occupant 
provides fixed carbon and nitrogen. 
“There is a lot of very intimate 
signaling,” says McDermott. “They 
seem to be truly dependent, and 
don’t like to grow apart.” 
The existence of the signaling 
pathways suggests that the fungi 
may make molecules that can 
modify signaling pathways in both 
lichens and, potentially, humans. 
And such molecules are unlikely to 
have been previously described. 
“About one fifth of fungi are in 
lichen associations,” says 
McDermott, “and these have never 
really been looked at because they 
can’t be cultured. [Looking at 
lichens] was a natural extension of 
looking at [the uncultured bacteria 
in] soils.” 
Expression hosts for the lichen 
DNA are species of the molds 
Aspe~gdhs or Newospora. TerraGen 
has used the soil and lichen DNA in 
cell-based assays to find a number of 
promising natural products in three 
different compound classes. Some of 
these products target either MAP or 
src kinases, both possible anti-cancer 
targets. The major emphasis of the 
company will, however, be on 
supplying libraries to other 
companies for various screens. 
A more focussed approach 
Both TerraGen and ChromaXome 
select for large fragments of DNA 
with genes similar to known 
biosynthetic pathways. Although 
they will not disclose all of the 
genes that are selected for, one of 
the most common targets are the 
polyketide synthases. Polyketides 
are built up by stepwise 
combination of small carbon 
building blocks, to yield drugs that 
kill bacteria (tetracycline, 
erythromycin, rifamycin), fungi 
(amphotericin B, nystatin), or cancer 
cells (daunorubicin, adriamycin), 
suppress the immune system 
(FK.506, rapamycin), or lower 
cholesterol levels (Mevacor). 
Manipulating polyketide pathways 
is the sole focus of Kosan 
Biosciences, Inc. (Burlingame, 
California). Kosan shuffles genes 
that are part of the same pathway 
but from different organisms, an 
approach that ChromaXome is also 
interested in. Kosan recently 
demonstrated that polyketide 
pathways can utilize synthetic 
building blocks. This should allow 
chemists and biologists to join forces 
to construct novel, ‘unnatural 
natural products’. 
Staking out territory 
The natural products may be many, 
but the techniques used to isolate the 
chunks of DNA are few. TerraGen 
has been working in the field for 
longer and has a number of patent 
applications pending, but the first 
notice of allowance, the precursor to a 
patent, was awarded to ChromaXome 
in September 1997. Sherman says the 
patent covers a number of aspects of 
combinatorial biology, including both 
screening methods and the 
generation of libraries from mixed 
pools of genomic DNA isolated 
directly from the soil. But for now 
TerraGen’s McDermott is confident 
that there will be room for his 
company to maneuver. “I don’t see it 
as a major conflict,” he says. “There 
is plenty of room for a number of 
players in this field.” 
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